Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients

BMC Cancer

Research

Wenjing Mu¹  Zipeng Zhuo²  Yu Xin³  Changsong Wang³  Yuxin Zhou³  Hongxu Li³  Chen Wang⁴ 

[1] Department of Anesthesiology, Zhujiang Hospital of Southern Medical University, 510280, Guangdong, Guangzhou Province, China;Department of Critical Care Medicine, the Cancer Hospital of Harbin Medical University, 150081, Harbin, Heilongjiang Province, China;Department of Critical Care Medicine, the Cancer Hospital of Harbin Medical University, 150081, Harbin, Heilongjiang Province, China;Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University, 150001, Harbin, Heilongjiang Province, China;Department of Digestive medicine center, The Seventh Affiliated Hospital, Sun Yat-sen University, 518017, Shenzhen, China;

关键词: Chimeric antigen receptor T cell therapy;    Programmed cell death protein-1;    Lymphoma;    Efficacy;    Safety;    Immunotherapy;   

DOI  :  10.1186/s12885-023-11536-4

 received in 2023-08-03, accepted in 2023-10-17,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundChimeric antigen receptor T (CAR-T) cell therapy, a new adoptive cell therapy, has been widely used to treat lymphoma patients. Immune checkpoint blockade may improve the cytotoxicity of CAR-T cells by reducing the failure of CAR-T cells and improving antitumor activity. It has shown promising efficacy.MethodWe searched PubMed, the Cochrane Library, Embase and Web of Science from January 2012 to August 2022 to find data reporting the results of CAR-T cells therapy combined with PD-1 in tumor patients. An updated search was conducted in October 2023. The partial response rate (PR), complete response rate (CR), objective response rate (ORR), mortality rate, and incidence of adverse reactions were calculated.ResultsWe analyzed 57 lymphoma patients from 5 clinical trials. The pooled partial, complete and overall response rates were 21% (95% CI 0.06–0.39, I2 = 0.37%), 27% (95% CI 0.03–0.60, I2 = 60.43%) and 65% (95% CI 0.23–0.98, I2 = 76.31%), respectively. The pooled incidence of cytokine release syndrome, neutropenia, fever, and fatigue was estimated to be 57% (95% CI 0.08–0.99, I2 = 85.20%), 47% (95% CI 0.14–0.81, I2 = 74.17%), 59% (95% CI 0.27–0.89, I2 = 60.23%), and 50% (95% CI 0.13–0.87, I2 = 73.89%), respectively.ConclusionCAR-T-cell therapy combined with anti-PD-1 immunotherapy in the treatment of lymphoma patients has efficacy, and the most common adverse effect is fever.RegistrationThe protocol was registered in prospero, with the registration number CRD42022342647.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1

Fig. 14

Fig. 11

12936_2017_1882_Article_IEq9.gif

Fig. 2

12951_2016_246_Article_IEq13.gif

Fig. 9

12951_2017_255_Article_IEq51.gif

Fig. 1